When PD-1 binds to PD-L1, activated T cells receive inhibitory signals and cease to produce anti-tumor immune responses (21), rendering PD-L1 a potentially promising target for the cancer immunotherapy (24, 25). This evidence concerns the gene CD274 and cancer.